Health Economics›T-cell prolymphocytic leukemia›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

T-cell prolymphocytic leukemia · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Venetoclax Variant #01	—	R 200 392	28d	~31.3 mo	—	~78	~R 13 598 349 PFS proxy · indirect	10
Pentostatin and Alemtuzumab Variant #01 Partial	—	R 146 007	7d	—	—	~12	~R 949 046 indirect	—
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~6	~R 42 504 PFS proxy · indirect	2

3 of 3 regimens shown